Pediapharm Announces Results of AGM and Director Changes

MONTREAL, QUEBEC--(Marketwired - Sept. 22, 2017) -

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Pediapharm Inc. (TSX VENTURE:PDP) ("Pediapharm" or the "Company") is pleased to announce the results of its recent annual general meeting of shareholders, which was held on September 22, 2017. Shareholders approved the size of the Board of Directors of the Company (the "Board"), the election of each director nominee, the appointment of PricewaterhouseCoopers LLP, Chartered Accountants as the auditors of the Company and the ratification of the Company's stock option plan.

Changes in Directors

Mr. Pierre Desormeau did not stand for re-election as a director of the Company to pursue other matters. The Board would like to thank Mr. Desormeau for his invaluable contribution to the success of Pediapharm since it was founded and wish him well in his future endeavors.

Mr. Benoit Gravel was elected to the Board for the first time. Benoit Gravel began his career as an economist in the Energy and Transportation industries in Canada with Hydro-Québec and VIA Rail. He joined the pharmaceutical industry 30 years ago at Rhône-Poulenc in Montreal as Director, Corporate Planning & Business Development. He spent 3 years in Paris in Global Business Development and returned to Canada as Vice-President, External Affairs, Vice-President Finance and President. At the creation of Aventis he was appointed Vice-President, Commercial Affairs. After a merger with Sanofi, he held several commercial executive positions in Canada, his last Canadian position being Vice-President Diabetes & Specialized Care Patient Centered Unit. His last assignment with Sanofi before retirement was Vice-President, Global Portfolio Management & Strategic Development based in Prague, Czech Republic in the Global Generics division. Benoit has a Bachelor and Master degree in Economics from University of Montréal.

The Board has approved the grant of 100,000 stock options to Mr. Benoit Gravel. The options were issued with an exercise price of $0.30 per share and have a term of ten (10) years. In addition, the options have vesting provisions such that they vest over two (2) years.

The option grant is subject to regulatory and TSX Venture Exchange approval.

About Pediapharm Inc.

Pediapharm is the only Canadian specialty pharmaceutical company dedicated to serving the needs of the pediatric community. Its mission is to bring to the Canadian market the latest innovative pediatric products with the objective to improve the health and the well-being of children in Canada. Since its debut in 2008, Pediapharm has entered into numerous commercial agreements with partners from Canada and other countries around the world. The Company's innovative product portfolio includes NYDA®, a breakthrough treatment for head lice; EpiCeram®, a non-steroid emulsion for eczema; naproxen suspension, indicated to treat pain and inflammation due to various conditions, including Juvenile Idiopathic Arthritis; Rupall™, an innovative new allergy medication with a unique mode of action; Otixal™, the first and only antibiotic and steroid combination ear drop available in single, sterile, preservative-free and unit-dose packaging; and Cuvposa™, for severe drooling, which is under review with Health Canada.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.